Dr. Patil on ADAURA Data with Osimertinib in NSCLC

Partner | Cancer Centers | <b>Cleveland Clinic</b>

Pradnya D. Patil, MD, FACP, discusses data from the phase 3 ADAURA trial in patients with EGFR-mutated non–small cell lung cancer.

Pradnya D. Patil, MD, FACP, Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, discusses data from the phase 3 ADAURA trial (NCT02511106) in patients with EGFR-mutated non–small cell lung cancer (NSCLC).

The ADAURA trial yield data that showed an improvement in disease-free survival (DFS) with the addition of osimertinib (Tagrisso) after the completion of adjuvant chemotherapy in patients with completely resected, EGFR-mutated, nonsquamous NSCLC, according to Patil. Additionally, although the overall survival has not yet been reported, osimertinib is still a feasible option in this setting given the impressive DFS data, Patil says. However, more data are needed to determine if there is an OS benefit with the agent, Patil continues.

Additionally, it is important to consider how to balance toxicities, how to overcome osimertinib resistance, and what additional options are available if a patient develops metastatic disease, Patil says. Overall, the ADAURA trial produced encouraging data for this patient population, Patil concludes.